Cytarabine

Evidence Level: L4

Predicted Indications: 9

Cytarabine

Pharmacist Assessment Report

Cytarabine: From Acute Leukaemia to Small Cell Lung Carcinoma

One-Sentence Summary

Cytarabine is a pyrimidine nucleoside analogue originally used to treat acute lymphoblastic and acute myeloid leukaemias. The TxGNN model predicts it may be effective for small cell lung carcinoma, but there are 0 registered clinical trials and no SCLC-specific cytarabine publications among the 20 retrieved publications, so the evidence rests on the model prediction alone.

Quick Overview

Item	Content
Original Indication	Acute lymphoblastic leukaemia and acute myeloid leukaemia (including several AML subtypes)
Predicted New Indication	Small cell lung carcinoma
TxGNN Prediction Score	0.9978
Evidence Level	L4
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Note: the data compiled for this report list no approved indication text for the Australian product, so the original indication above comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, cytarabine is a pyrimidine nucleoside analogue that inhibits DNA synthesis in cells in S-phase. Its efficacy in acute leukaemias is established, and mechanistically it may be applicable to rapidly proliferating tumours such as small cell lung carcinoma.

However, the supporting evidence is weak. The retrieved literature mainly concerns non-small cell lung cancer (NSCLC), not SCLC. It includes 1990 phase II studies of cytarabine with cisplatin (one reporting a 14% overall response rate with substantial myelosuppression), leptomeningeal disease, and other antimetabolites (gemcitabine, decitabine, topotecan). One 1987 publication (PMID 3030547) is titled “High-dose cytarabine in small cell lung cancer”, but no abstract or outcome data were retrieved. The very high model score is therefore not supported by clinical evidence at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2156598	1990	Phase II trial	Cancer	High-dose cytarabine plus cisplatin in 37 chemotherapy-naive NSCLC patients: overall response rate 14%; grade IV myelosuppression in 32%; 4 deaths on study
2158614	1990	Randomised phase II	Med Pediatr Oncol	CALGB trial of cisplatin-cytarabine vs cisplatin-vinblastine in 151 patients with advanced NSCLC
2157307	1990	Phase II trial	Tumori	Cisplatin, vindesine and cytarabine in 32 patients with advanced NSCLC
3030547	1987	Not classified	Cancer Treat Rep	“High-dose cytarabine in small cell lung cancer”; no abstract available
2820740	1987	Pilot study	Eur J Cancer Clin Oncol	Cisplatin and cytarabine combination in advanced NSCLC; no abstract available
9561978	1998	Case series/Review	Arch Neurol	Combined modality therapy for carcinomatous meningitis from NSCLC
38377785	2024	Phase II (single arm)	ESMO Open	Intrathecal pemetrexed for leptomeningeal metastases from EGFR+ NSCLC (not cytarabine)
1332622	1992	Review	Gan To Kagaku Ryoho	Gemcitabine and DMDC, cytarabine-related antimetabolites; many solid tumours are insensitive to cytarabine

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 4357H	Pfizer Australia Pty Ltd	Injection 100 mg in 5 mL vial	Not available

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (pyrimidine nucleoside antimetabolite)
Myelosuppression Risk	High (grade IV myelosuppression in 32% in a high-dose cytarabine plus cisplatin lung cancer study)
Emetogenicity Classification	Nausea and vomiting reported as a principal toxicity in the same study; please refer to the Product Information (PI)
Monitoring Items	Full blood count with differential; liver and renal function
Handling Protection	Must follow cytotoxic drug handling requirements

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications.

Conditions flagged in the knowledge graph (not label text): kidney disease, liver disease, pancreatitis, gallbladder disease, thrombocytopenia, anaemia, leukopenia, neutropenia and agranulocytosis (including congenital neutropenia syndromes), peripheral neuropathy, fungal infections, diarrhoeal disease, pulmonary oedema, and necrotising enterocolitis.
Drug interactions: the interaction screen returned 100 entries. Those listed were mostly of unknown severity. The only graded ones were naltrexone (moderate) and levofloxacin (minor). Please verify interactions against the PI and a current interaction reference.

Conclusion and Next Steps

Decision: Hold

Rationale: There are no registered trials, and no SCLC-specific cytarabine outcome data were retrieved. The related lung cancer studies were in NSCLC, were over 30 years old, showed modest activity, and caused significant myelosuppression. The high TxGNN score alone is insufficient to justify progression.

To proceed, the following is needed:

Retrieval and review of the full text of the 1987 high-dose cytarabine in SCLC report (PMID 3030547)
Mechanism of action data
Package insert warnings and contraindications from the TGA-approved PI
Comparison against current standard-of-care SCLC regimens
Preclinical or early clinical data specific to SCLC

Other predicted indications (for context): all other predictions were also rated Hold or lower in strength.

Primary pulmonary lymphoma: evidence is indirect (CNS lymphoma regimens, L4).
Upper aerodigestive tract neoplasm: evidence is indirect (L4).
Retroperitoneal neoplasm: evidence is indirect (L4).
Well-differentiated fetal adenocarcinoma of the lung, pulmonary blastoma, ganglioneuroblastoma, the vertebral anomalies and endocrine/T-cell dysfunction syndrome, and the CLL/SLL subtype: prediction only, no evidence (L5).
Neuroblastoma: the strongest of the secondary candidates (L3, a research question). Preclinical cytarabine activity is reported in neuroblastoma cell lines, but the three registered early-phase trials involve other interventions and do not confirm a cytarabine role.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.